Cargando…
FSHD Therapeutic Strategies: What Will It Take to Get to Clinic?
Facioscapulohumeral muscular dystrophy (FSHD) is arguably one of the most challenging genetic diseases to understand and treat. The disease is caused by epigenetic dysregulation of a macrosatellite repeat, either by contraction of the repeat or by mutations in silencing proteins. Both cases lead to...
Autores principales: | Himeda, Charis L., Jones, Peter L. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9225474/ https://www.ncbi.nlm.nih.gov/pubmed/35743650 http://dx.doi.org/10.3390/jpm12060865 |
Ejemplares similares
-
Targeted epigenetic repression by CRISPR/dSaCas9 suppresses pathogenic DUX4-fl expression in FSHD
por: Himeda, Charis L., et al.
Publicado: (2020) -
Therapeutic Strategies Targeting DUX4 in FSHD
por: Le Gall, Laura, et al.
Publicado: (2020) -
Current Therapeutic Approaches in FSHD
por: Wang, Leo H., et al.
Publicado: (2021) -
Precise Epigenetic Analysis Using Targeted Bisulfite Genomic Sequencing Distinguishes FSHD1, FSHD2, and Healthy Subjects
por: Gould, Taylor, et al.
Publicado: (2021) -
Genotype-phenotype correlations in FSHD
por: Zernov, Nikolay, et al.
Publicado: (2019)